Alloimmune hemolytic disease of the fetus and newborn: genetics, structure, and function of the commonly involved erythrocyte antigens

J Perinatol. 2023 Dec;43(12):1459-1467. doi: 10.1038/s41372-023-01785-3. Epub 2023 Oct 17.

Abstract

Hemolytic disease of the fetus and newborn (HDFN) can occur when a pregnant woman has antibody directed against an erythrocyte surface antigen expressed by her fetus. This alloimmune disorder is restricted to situations where transplacental transfer of maternal antibody to the fetus occurs, and binds to fetal erythrocytes, and significantly shortens the red cell lifespan. The pathogenesis of HDFN involves maternal sensitization to erythrocyte "non-self" antigens (those she does not express). Exposure of a woman to a non-self-erythrocyte antigen principally occurs through either a blood transfusion or a pregnancy where paternally derived erythrocyte antigens, expressed by her fetus, enter her circulation, and are immunologically recognized as foreign. This review focuses on the genetics, structure, and function of the erythrocyte antigens that are most frequently involved in the pathogenesis of alloimmune HDFN. By providing this information we aim to convey useful insights to clinicians caring for patients with this condition.

Publication types

  • Review

MeSH terms

  • Erythroblastosis, Fetal* / genetics
  • Erythrocytes
  • Female
  • Fetus
  • Hemolysis
  • Humans
  • Infant, Newborn
  • Isoantibodies*
  • Pregnancy

Substances

  • Isoantibodies